Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Dactinomycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.99 |
| ▸ | GRB2 | P62993 | 3/20 | 0.99 |
| ▸ | MAPT | P10636 | 2/20 | 0.99 |
| ▸ | RECQL | P46063 | 2/20 | 0.99 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.99 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.99 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.99 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.99 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.99 |
| ▸ | CASP1 | P29466 | 1/20 | 0.99 |
| ▸ | HTT | P42858 | 1/20 | 0.99 |
| ▸ | BLM | P54132 | 1/20 | 0.99 |
| ▸ | CASP7 | P55210 | 1/20 | 0.99 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.99 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.99 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.99 |
| ▸ | NGLY1 | Q96IV0 | 1/20 | 0.99 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dactinomycin SCHEMBL13659669 | 0.99 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL6939686 | 0.99 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL26186613 | 0.99 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL3845 | 0.99 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL19770615 | 0.99 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL6152 | 0.99 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL27304406 | 0.99 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL3844 | 0.99 | GRB2 (1.00) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL28168861 | 0.99 | GRB2 (0.99) | GRB2MAPTRECQLSMN1; SMN2ABCB11 | |
| Dactinomycin SCHEMBL28161860 | 0.98 | GRB2 (0.98) | GRB2MAPTRECQLSMN1; SMN2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872313-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-01-16 | — | — | US | disclosed |
| US-11141379-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2021-10-12 | — | — | US | disclosed |
| US-20210077400-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-03-18 | — | — | US | disclosed |
| US-20190192436-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-06-27 | — | — | US | disclosed |
| US-10259884-B2 | Antibodies to GRP78 | WASHINGTON UNIVERSITY (US) | 2019-04-16 | — | — | US | disclosed |
| US-10201500-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170298142-A1 | ANTIBODIES TO TIP-1 AND GRP78 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-10-19 | — | — | US | disclosed |
| US-9738725-B2 | Antibodies to TIP-1 | WASHINGTON UNIVERSITY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9498439-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2016-11-22 | — | — | US | disclosed |
| US-9468607-B2 | Ligand directed toroidal nanoparticles for therapy and diagnostic imaging | WASHINGTON UNIVERSITY (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160279060-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-29 | — | — | US | disclosed |
| US-9446150-B2 | Particles for imaging | WASHINGTON UNIVERSITY (US) | 2016-09-20 | — | — | US | disclosed |
| US-20140316186-A1 | ANTIBODIES TO TIP-1 AND GRP78 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-10-23 | — | — | US | disclosed |
| US-20130122100-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | THE WASHINGTON UNIVERSITY (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2013019730-A1 | ANTIBODIES TO TIP-1 AND GRP78 | THE WASHINGTON UNIVERSITY (US) | 2013-02-07 | — | — | WO | disclosed |
| US-20100297019-A1 | PARTICLES FOR IMAGING | THE WASHINGTON UNIVERSITY (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100297007-A1 | LIGAND DIRECTED TOROIDAL NANOPARTICLES FOR THERAPY AND DIAGNOSTIC IMAGING | THE WASHINGTON UNIVERSITY (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2009117688-A2 | METHODS FOR PRODUCING MICROBUBBLES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279060-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | FAP, PNP, TYMP | PTGS1 1096/4885GRB2 4834/4885MAPT 1745/4885 |
| US-20130122100-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | PHOSPHO1, PTDSS1, SMPD3 | PTGS1 1169/4885GRB2 3481/4885MAPT 2188/4885 |
| US-20190192436-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | FAP, PNP, TYMP | PTGS1 1096/4885GRB2 4834/4885MAPT 1745/4885 |
| US-11141379-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | FAP, PNP, TYMP | PTGS1 1096/4885GRB2 4834/4885MAPT 1745/4885 |
| US-20210077400-A1 | PRODRUG COMPOSITIONS, PRODRUG NANOPARTICLES, AND METHODS OF USE THEREOF | FAP, PNP, TYMP | PTGS1 1096/4885GRB2 4834/4885MAPT 1745/4885 |
| US-10201500-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | FAP, PNP, TYMP | PTGS1 1096/4885GRB2 4834/4885MAPT 1745/4885 |
| US-11872313-B2 | Prodrug compositions, prodrug nanoparticles, and methods of use thereof | FAP, PNP, TYMP | PTGS1 1096/4885GRB2 4834/4885MAPT 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.